Business Wire

PCI Pharma Services Opens New England Center of Excellence to Bring Global Clinical Supply Capabilities to New England

Share

PCI Pharma Services (PCI), a leading global contract development and manufacturing organization (CDMO), today announced the opening of its Clinical Services Center of Excellence in Bridgewater, MA, the first facility of its kind to support the growing needs of global developers of biologics in the New England region. The new facility will provide increased flexibility and scalability for secondary packaging, distribution and cold chain storage of innovative therapies in development.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220825005234/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Rendering of the new PCI facility in Bridgewater, MA. (Photo: Business Wire)

“As the northeast biopharma market continues to grow, we are bringing distinctive clinical supply capabilities to the backyard of product development, creating a personalized and responsive approach to evolving client needs,” said Salim Haffar, CEO, PCI Pharma Services. “This newest facility follows our growth in facilities in Berlin, Germany, and Rockford, Illinois, and will create significant local job growth potential.”

To keep pace with the growth in biologics and gene therapies, which require cold chain infrastructure including deep freeze, the new facility has a capacity for a -20°C freezer, 35 ultra-low temperature freezers at -80°C and 12 liquid nitrogen freezers. The Center of Excellence also features a temperature-controlled room containing a 5,000 square foot cooler at 2° to 8°C, each with five levels of warehouse racking. A 1000-square-foot cold secondary packaging room will eventually be converted to primary packaging with the planned construction of an additional secondary packing unit.

“Boston is a booming biotech market with hundreds of local organizations developing new compounds in the biologics space,” said Craig LaMarca, General Manager of Boston Clinical Trial Services, PCI Pharma Services. “The facility features leading technologies and capabilities, making it a crucial component to help our clients deliver life-saving therapies to patients safely and efficiently.”

PCI currently occupies 50,000 square feet of the new 100,000 square foot building, with the remaining space available for lease. The campus was constructed to reflect Environmental Social Governance (ESG) and sustainability efforts. These features include a complex stormwater runoff system with a series of ponds that filter the water before it leaves the site, an underground oil and sedimentation separation tank, electric vehicle chargers and the exclusive use of LED lighting throughout the building.

The opening of the New England Center of Excellence marks the latest in a series of worldwide expansions for PCI including six sites across three continents, including Bedford, New Hampshire; Berlin, Germany; San Diego, California; Rockford, Illinois; and Melbourne, Australia. In February 2022, PCI sites in San Diego and Melbourne added innovative equipment with aseptic fill-finish capabilities to enhance PCI’s global offerings and deliver much-needed capacity to early-phase clinical clients.

For more information on PCI’s aseptic fill-finish and lyophilization capabilities, please click here.

About PCI Pharma Services

PCI is a leading global CDMO, providing clients with integrated end-to-end drug development, manufacturing and packaging capabilities that increase their products’ speed to market and opportunities for commercial success. PCI brings the proven experience that comes with more than 50 successful product launches each year and over five decades in the healthcare services business. We currently have 30 sites across seven countries (Australia, Canada, U.S., Ireland, Wales, Germany and Spain) and over 4,300 employees that work to bring life-changing therapies to patients. Leading technology and continued investment enable us to address global drug development needs throughout the entire product life cycle – from manufacturing capabilities through the clinical trial supply chain and into commercialization. Our clients view us as an extension of their business and a collaborative partner with the shared goal of improving patients’ lives.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Ty Guzman-Touchberry, WE Communications
tgtouchberry@we-worldwide.com / +1-212-551-4877

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

IFF Reports First Quarter 2024 Results7.5.2024 00:27:00 EEST | Press release

IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2024. Management Commentary "We have started the year well, with good results across the majority of our business," said IFF CEO Erik Fyrwald. "In the first quarter, we delivered volume growth and productivity gains, which resulted in solid top-and-bottom-line results on a comparable basis. We are off to a good start, yet recognize that it is still early in the year and uncertainty remains. Based on our performance to date and our outlook for the balance of the year, we believe results will likely trend towards the higher-end of our previously announced guidance ranges. We also took important steps in our portfolio optimization strategy by reaching an agreement to sell our Pharma Solutions business and completing the previously announced divestiture of our Cosmetic Ingredients business. These actions, along with the rightsizing of our dividend earlier this year, represent significant steps toward our commi

IFF Chief Financial and Business Transformation Officer Glenn Richter to retire year end 20246.5.2024 23:16:00 EEST | Press release

IFF (NYSE: IFF) today announced that Glenn Richter, IFF’s Chief Financial and Business Transformation Officer, plans to retire Dec. 31, 2024 after a three-year tenure with the company. A succession process has been initiated to evaluate internal and external candidates to succeed Richter as CFO. “During his time at IFF, Glenn has driven multiple actions to improve our balance sheet and position the company for financial success,” said Erik Fyrwald, IFF CEO. “We have benefited from his experience and commitment to transformation. Notably, the work he has led on portfolio optimization, strategy development and our shared services agenda have positioned IFF to drive long-term profitable market share growth. The Board and I are grateful for all Glenn has helped IFF accomplish, and we appreciate his ongoing leadership of the finance function and support in identifying his successor and ensuring a smooth transition.” Richter has been with IFF since 2021, leading global finance. Before joinin

The Empire State Building Partners with Outward Bound on First-Ever, Full Rappel Down the Building for Charity6.5.2024 21:34:00 EEST | Press release

The Empire State Building (ESB) hosted 20 brave supporters of Outward Bound – along with participant Jared Leto – in a historic rappel down the building’s south façade, in partnership with Outward Bound to raise transformational funds for the charity across the world. Participants total donations exceeded $3 million to Outward Bound, which will make a profound difference in the educational journeys of young people everywhere. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240506846659/en/ The Empire State Building Partners with Outward Bound on First-Ever, Full Rappel Down the Building for Charity (Photo: Business Wire) “The Empire State Building is the perfect host to amplify Outward Bound’s charitable mission through this historic rappel, and it reaffirms the Empire State Building’s long-held status as a symbol of hope, strength, and resilience,” said Tony Malkin, chairman and CEO of Empire State Realty Trust. “My wife and

Armis Wins 6 Global InfoSec Awards at RSAC 2024, Named “Hot” Cybersecurity Company6.5.2024 19:10:00 EEST | Press release

Armis, the asset intelligence cybersecurity company, today announced that it has won six Global InfoSec Awards from Cyber Defense Magazine at this year’s RSA Conference. Armis received the following accolades: Armis named “Hot Cybersecurity Company” Nadir Izrael, Armis’ Co-Founder and CTO, awarded “Cutting Edge Chief Technology Officer” Armis Centrix™ won multiple awards: “Cutting Edge” platform accolade in the Cyber Exposure Management category “Best Product” for Attack Surface Management “Next Gen” product for Vulnerability Prioritization and Remediation The Armis AI-powered Asset Intelligence Engine received a “Publisher’s Choice” award in the category recognizing AI Platforms for Cybersecurity Strategy Analytics “These accolades reinforce Armis’ dedication to innovation and our commitment to helping our customers solve their biggest cybersecurity problems through one comprehensive platform,” said Yevgeny Dibrov, CEO and Co-Founder of Armis. “Armis will continue to push the boundari

Edgio Named Winner of the Coveted Global InfoSec Awards During RSA Conference 20246.5.2024 19:00:00 EEST | Press release

Edgio is proud to announce it has received the Web Application Security award from Cyber Defense Magazine (CDM), the industry’s leading electronic information security magazine. According to Verizon’s Data Breach Investigation Report (DBIR), over 60% of data breaches were attributed to web applications, underscoring the urgent need for organizations to continuously manage threat exposure across their web applications and throughout the entire DevSecOps lifecycle. Committed to addressing the complex and evolving needs of organizations, Edgio continues to innovate and expand its services with its recent launch of Attack Surface Management (ASM) - a solution designed to discover all web assets, provide full inventory of technologies, detect security exposures and manage exposure response across an organization from a centralized management interface. ASM, coupled with Edgio’s holistic web security solutions and managed security services provide the industry’s first edge-enabled continuous

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye